← All trials
NCT04050540
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Sep 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 446
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of California, San FranciscoCollaborator
- University of WashingtonOverall official - principal investigator
- University of WashingtonReponsible party - principal investigator
- Kenya Medical Research InstituteCollaborator
- Kenya National AIDS & STI Control ProgrammeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.